Search Filters:

The items contained in the list are being used to filter the search results. Click them to remove them from the search filter.
Displaying 21 - 40 of 257
PIPS Search Results
PIP Number Active Substance Conditions / Indications Invented Name Therapeutic area Decision Type Compliance Check Compliance outcome Date Published Sort ascending
MHRA-100023-PIP01-21-M02 (update)
  • bimekizumab
  • Treatment of psoriasis
  • Bimzelx
  • Bimzelx
  • Bimzelx
  • Dermatology
PM: decision on the application for modification of an agreed paediatric investigation plan. Yes Partial Compliance Check Granted
MHRA-101661-PIP01-24
  • RUXOLITINIB PHOSPHATE
  • Treatment of atopic dermatitis
  • OPZELURA
  • OPZELURA
  • OPZELURA
  • OPZELURA
  • OPZELURA
  • Dermatology
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) Yes Partial Compliance Check Granted
MHRA-100249-PIP01-21-M04 (update)
  • BUDESONIDE
  • GLYCOPYRRONIUM
  • FORMOTEROL FUMARATE DIHYDRATE
  • Treatment of asthma
  • Trixeo Aerosphere
  • Trixeo Aerosphere
  • Trixeo Aerosphere
  • BREZTRI AEROSPHERE
  • BREZTRI AEROSPHERE
  • Pneumology - Allergology
PM: decision on the application for modification of an agreed paediatric investigation plan. Yes Partial Compliance Check Granted
MHRA-100840-PIP01-23-M01 (update)
  • Odronextamab
  • Treatment of mature B cell malignancies
  • Oncology
PM: decision on the application for modification of an agreed paediatric investigation plan. Yes Partial Compliance Check Granted
MHRA-102181-PIP01-25
  • Tinlarebant
  • Treatment of Stargardt disease
  • Ophthamology
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) Yes Partial Compliance Check Granted
MHRA-102467-PIP01-26-M01 (update)
  • HUMAN FIBRINOGEN
  • Treatment of congenital fibrinogen deficiency
  • Fesilty 1 g Powder and solvent for solution for injection/infusion
  • Fesilty
  • Haematology-Hemostaseology
PM: decision on the application for modification of an agreed paediatric investigation plan. Yes Full Compliance Check Granted
MHRA-101249-PIP01-23-M01 (update)
  • Tovorafenib
  • Treatment of paediatric low grade glioma
  • Oncology
PM: decision on the application for modification of an agreed paediatric investigation plan. Yes Partial Compliance Check Granted
MHRA-101513-PIP01-24-M02 (update)
  • ERTUGLIFLOZIN L-PYROGLUTAMIC ACID
  • Treatment of Type 2 Diabetes Mellitus
  • Steglatro
  • Steglatro
  • Steglatro
  • Steglatro
  • Steglatro
  • Steglatro
  • Steglatro
  • Steglatro
  • Steglatro
  • Steglatro
  • Steglatro
  • Steglatro
  • Steglatro
  • Steglatro
  • Steglatro
  • Steglatro
  • Endocrinology-Gynaecology-Fertility-metabolism
PM: decision on the application for modification of an agreed paediatric investigation plan. Yes Full Compliance Check Granted
MHRA-100993-PIP01-23-M03 (update)
  • QUIZARTINIB DIHYDROCHLORIDE
  • Treatment of acute myeloid leukaemia
  • VANFLYTA
  • VANFLYTA
  • Oncology
PM: decision on the application for modification of an agreed paediatric investigation plan. Yes Partial Compliance Check Granted
MHRA-102514-PIP01-26-M01 (update)
  • Concentrate of proteolytic enzyme enriched in in bromelain
  • Treatment of burns.
  • Nexobrid
  • Dermatology
PM: decision on the application for modification of an agreed paediatric investigation plan. Yes
MHRA-102324-PIP01-26-M01 (update)
  • CABOZANTINIB
  • Treatment of malignant solid tumours
  • Cabometyx
  • Oncology
PM: decision on the application for modification of an agreed paediatric investigation plan. Yes
MHRA-101647-PIP01-24-M01 (update)
  • IXEKIZUMAB
  • Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylarthritis and juvenile idiopathic arthritis)
  • Taltz
  • Taltz
  • Taltz
  • Immunology -Rheumatology-Transplantation
PM: decision on the application for modification of an agreed paediatric investigation plan. Yes Full Compliance Check Granted
MHRA-101641-PIP01-24
  • Japanese encephalitis virus, strain SA14-14-2, Live
  • Prevention of Japanese encephalitis
  • IMOJEV
  • IMOJEV
  • IMOJEV
  • Infectious diseases
  • Vaccines
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) Yes Full Compliance Check Granted
MHRA-101618-PIP01-24-M02 (update)
  • ADRENALINE
  • Treatment of allergic reactions
  • EURneffy 2 mg nasal spray, solution in single-dose container
  • EURneffy 2 mg nasal spray, solution in single-dose container
  • EURneffy 2 mg nasal spray, solution in single-dose container
  • NEFFY
  • Pneumology - Allergology
PM: decision on the application for modification of an agreed paediatric investigation plan. Yes Partial Compliance Check Granted
MHRA-101543-PIP01-24-M01 (update)
  • SELUMETINIB HYDROGEN SULFATE
  • Treatment of neurofibromatosis type 1
  • Treatment of thyroid cancer
  • Treatment of melanoma
  • Koselugo
  • Koselugo
  • Koselugo
  • Koselugo
  • Koselugo
  • Koselugo
  • Koselugo
  • Koselugo
  • Koselugo
  • Koselugo
  • Koselugo
  • Koselugo
  • Koselugo
  • Koselugo
  • Koselugo
  • Koselugo
  • Koselugo
  • Koselugo
  • Koselugo
  • Koselugo
  • Koselugo
  • Koselugo
  • Koselugo
  • Koselugo
  • Koselugo
  • Koselugo
  • Koselugo
  • Koselugo
  • Koselugo
  • Koselugo
  • Koselugo
  • Koselugo
  • Oncology
PM: decision on the application for modification of an agreed paediatric investigation plan. Yes Full Compliance Check Granted
MHRA-101509-PIP01-24
  • Ferric Citrate Coordination Complex
  • Treatment of anaemias due to chronic kidney disorders
  • Xoanacyl
  • Auryxia
  • Riona
  • Nephoxil
  • Nephoxil
  • Uro-Nephrology
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) Yes Partial Compliance Check Granted
MHRA-101495-PIP01-24
  • Split influenza virus, inactivated containing antigens equivalent to the A/H1N1-like strain
  • Split influenza virus, inactivated containing antigens equivalent to the A/H3N2-like strain
  • Split influenza virus, inactivated containing antigens equivalent to B-like strain
  • Prevention of influenza disease
  • not available
  • Vaccines
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) Yes Full Compliance Check Granted
MHRA-101489-PIP01-24-M02 (update)
  • Enlicitide (decanoate)
  • Treatment of lipid disorders
  • Cardiovascular Diseases
PM: decision on the application for modification of an agreed paediatric investigation plan. Yes Partial Compliance Check Granted
MHRA-101454-PIP01-24-M01 (update)
  • Donidalorsen
  • Treatment of hereditary angioedema
  • Pneumology - Allergology
  • Haematology-Hemostaseology
PM: decision on the application for modification of an agreed paediatric investigation plan. Yes Partial Compliance Check Granted
MHRA-101400-PIP01-24
  • nirogacestat hydrobromide
  • Treatment of soft tissue sarcoma
  • Not yet available in the United Kingdom (Ogsiveo in the United States and European Union).
  • Ogsiveo
  • Oncology
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) Yes Partial Compliance Check Granted